Search results
Order by most recent / most popular / relevance
Results: 11-20 of 82
Biosimilars market expected to increase by billions over next four years
- Shook Hardy & Bacon LLP
- -
- USA
- -
- April 7 2011
Market analysts have apparently forecast huge growth in the market for biosimilars due to the upcoming loss of patent exclusivity for a number of branded drugs
News bytes
- Shook Hardy & Bacon LLP
- -
- USA
- -
- April 7 2011
The U.S. Patent & Trademark Office implements prioritized examination of patent applications
Researchers protest ECJ advocate general’s position on patenting stem cell technologies
- Shook Hardy & Bacon LLP
- -
- European Union
- -
- May 5 2011
Viewing the issue as a matter of morality, the advocate general of the European Court of Justice (ECJ) recently delivered a non-binding ruling that would render unpatentable the cells removed from the human embryo at the blastocyst stage, because the removal involves the embryo's destruction
Is FTC considering fast-track rulemaking to stop “pay-for-delay” drug deals?
- Shook Hardy & Bacon LLP
- -
- USA
- -
- June 16 2011
According to a news source, the Federal Trade Commission (FTC) may be planning to adopt a rule under expedited procedures to block patent settlements, known as “pay-for-delay” deals, between name-brand drug manufacturers and generic drug makers
New forum for patent disputes?
- Shook Hardy & Bacon LLP
- -
- USA
- -
- March 24 2011
According to a news source, at least one major pharmaceutical company has filed a complaint before the International Trade Commission (ITC) seeking an exclusion order to block the importation of a generic version of one of its patented drugs
Pharma trade group seeks biologics data exclusivity for international trade
- Shook Hardy & Bacon LLP
- -
- USA
- -
- May 19 2011
PhRMA has reportedly called for the U.S. Trade Representative to go outside provisions in the Korea-U.S. trade deal (KORUS) and press for a 12-year period of exclusivity for biologics in ongoing Trans-Pacific Partnerships (TPP) negotiations
Court dismisses action to correct inventorship of two patents
- Shook Hardy & Bacon LLP
- -
- USA
- -
- May 19 2011
A federal court in Massachusetts has determined that genetic researchers could neither substitute themselves as the inventors of two patents nor correct the patents' inventorship to add their names under 35 U.S.C. 256, because they had not engaged in any collaborative efforts with the named inventors
False-marking plaintiff challenges retroactive application of AIA standing requirement
- Shook Hardy & Bacon LLP
- -
- USA
- -
- November 17 2011
A Benjamin N. Cardozo School of Law-affiliated non-profit legal services organization, known as the Public Patent Foundation, has filed a pleading in its false-marking lawsuit against the company that makes Tylenol products, challenging the constitutionality of a retroactive America Invents Act (AIA) provision that would divest the non-profit of standing
Court dismisses French company from suit seeking correction of patent inventorship
- Shook Hardy & Bacon LLP
- -
- USA
- -
- April 7 2011
A federal court in the District of Columbia has dismissed patent-related litigation against a French drug company for lack of personal jurisdiction
Violations of discovery orders result in default judgment, monetary sanctions, potential discipline
- Shook Hardy & Bacon LLP
- -
- USA
- -
- August 18 2011
A federal court in Texas has imposed severe sanctions in a patent infringement lawsuit, due to repeated violations of its discovery orders and the creation of a fraudulent discovery-related document; a default judgment has been entered against the violator, and information about the document has been forwarded to alert the district’s chief judge “of the need to potentially take disciplinary measures” against counsel
Current Search
- Workarea - Patents
- Workarea - Healthcare
- Author - Madeleine McDonough